Land: Irland
Sprog: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Triclabendazole
Elanco Europe Ltd
QP52AC
Triclabendazole
10 percent weight/volume
Oral suspension
LM: Licensed Merchant as defined in relevant national legislation
Cattle
Benzimidazoles and related substances
Endoparasiticide
Authorised
2016-10-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Fasinex 10% w/v Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Oral Suspension. White to cream-coloured suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Bovines. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment and control of adult, immature and early immature liver fluke. Target parasite species:_ Fasciola hepatica_ 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to the active substance. Do not use the product in sheep. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device. Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the tests strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Each ml comtains: Active Substance Triclabendazole 100 mg Excipients Methyl Parahydroxybenzoate (E218) 1.1 mg Propyl Parahydroxybenzoate (E216) 0.24 mg Benzoic Acid (E210) 1.0 mg H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Læs hele dokumentet